Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities (2024)

• ¹Good Clinical Practice Office, Guang’anmen Hospital China Academy of Chinese Medical Sciences, Beijing, China

  See Also

  Researchers track greenhouse gas emissions in Chinese value chains with an interprovincial input–output model31-year-old Mercy EMS Co-worker Recovers From Stroke That Occurred While On-duty | MercyMercy hiring Medical Assistant (Non-Exempt) (28303N) in St Louis, Missouri, United States | LinkedInMercy hiring Medical Assistant-Neurosurgery-Mercy South in St Louis, Missouri, United States | LinkedIn

• ²Department of Endocrinology, Guang’anmen Hospital China Academy of Chinese Medical Sciences, Beijing, China

• ³Department of Prevention and Treatment of Disease, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China

• ⁴Department of Endocrinology, Tangshan Gongren Hospital, Tangshan, China

• ⁵Department of Endocrinology, Hebei Yiling Hospital, Shijiazhuang, China

• ⁶Department of Traditional Chinese Medicine, Shijiazhuang 2nd Hospital, Shijiazhuang, China

• ⁷Department of General Practice, Baotou Central Hospital, Baotou, China

• ⁸Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China

• ⁹Department of Traditional Chinese Medicine, The First Affiliated Hospital of Medical College of Shihezi University, Shihezi, China

• ¹⁰Department of Endocrinology, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China

• ¹¹Department of Endocrinology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, China

• ¹²Department of Endocrinology, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China

• ¹³Department of Endocrinology, Tongliao City Horqin District First People’s Hospital, Tongliao, China

• ¹⁴Department of Endocrinology, Baoji Second People’s Hospital, Baoji, China

• ¹⁵Department of Endocrinology, Hebei Cangzhou Hospital of Integrated Chinese and Western Medicine, Cangzhou, China

• ¹⁶Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Nanjing, China

• ¹⁷Geriatrics Department, Liaocheng People’s Hospital, Liaocheng, China

• ¹⁸Department of Endocrinology, Second Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China

• ¹⁹Department of Endocrinology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China

• ²⁰Department of Biostatistics, Peking University First Hospital, Beijing, China

• ²¹Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China

• ²²NHC Key Laboratory of Hormones and Development, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China

• ²³Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China

• ²⁴Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China

• ²⁵Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yai-Sen University, Guangzhou, China

• ²⁶Metabolic Disease Institute, Guang’anmen Hospital China Academy of Chinese Medical Sciences, Beijing, China

• ²⁷State Key Laboratory for Innovation and Transformation of Luobing Theory of Hebei Yiling Hospital, Shijiazhuang, Hebei Province, China

Key Points

Question Can long-term use of Jinlida granules (JLD) reduce the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities?

Findings In this randomized clinical trial of 889 participants with IGT and multiple metabolic abnormalities, after a median follow-up of 2.20 years, the JLD group had a significantly lower risk of developing diabetes compared with the placebo group.

Meaning In participants with IGT combined with multiple metabolic disorders, JLD reduced the incidence of diabetes compared with placebo.

Importance Previous studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA_1c), and improve insulin resistance in people with type 2 diabetes.

Objective To evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities.

Design, Setting, and Participants This multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023. Individuals aged 18 to 70 years with IGT and multiple metabolic abnormalities were enrolled.

Intervention Participants were randomly allocated 1:1 to receive JLD or placebo (9 g, 3 times per day, orally). They continued this regimen until they developed diabetes, withdrew from the study, were lost to follow-up, or died.

Main Outcomes and Measures The primary outcome was the occurrence of diabetes, which was determined by 2 consecutive oral glucose tolerance tests. Secondary outcomes included waist circumference; fasting and 2-hour postprandial plasma glucose levels; HbA_1c; fasting insulin level; homeostatic model assessment for insulin resistance (HOMA-IR); total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels; ankle-brachial index; and carotid intima-media thickness.

Results A total of 889 participants were randomized, of whom 885 were in the full analysis set (442 in the JLD group; 443 in the placebo group; mean [SD] age, 52.57 [10.33] years; 463 [52.32%] female). Following a median observation period of 2.20 years (IQR, 1.27-2.64 years), participants in the JLD group had a lower risk of developing diabetes compared with those in the placebo group (hazard ratio, 0.59; 95% CI, 0.46-0.74; P < .001). During the follow-up period, the JLD group had a between-group difference of 0.95 cm (95% CI, 0.36-1.55 cm) in waist circumference, 9.2 mg/dL (95% CI, 5.4-13.0 mg/dL) in 2-hour postprandial blood glucose level, 3.8 mg/dL (95% CI, 2.2-5.6 mg/dL) in fasting blood glucose level, 0.20% (95% CI, 0.13%-0.27%) in HbA_1c, 6.6 mg/dL (95% CI, 1.9-11.2) in total cholesterol level, 4.3 mg/dL (95% CI, 0.8-7.7 mg/dL) in low-density lipoprotein cholesterol level, 25.7 mg/dL (95% CI, 15.9-35.4 mg/dL) in triglyceride levels, and 0.47 (95% CI, 0.12-0.83) in HOMA-IR compared with the placebo group. After 24 months of follow-up, the JLD group had a significant improvement in ankle-brachial index and waist circumference compared with the placebo group.

Conclusions and Relevance The findings suggest that JLD can reduce the risk of diabetes in participants with IGT and multiple metabolic abnormalities.

Trial Registration Chinese Clinical Trial Register: ChiCTR1900023241

Diabetes Diabetes and Endocrinology Cardiology Dyslipidemia Cardiovascular Risk Factors

Citation

Ji H, Zhao X, Chen X, et al. Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial. JAMA Intern Med. Published online June 03, 2024. doi:10.1001/jamainternmed.2024.1190

Manage citations:

© 2024